Home > News > Industry > Pharma News > Covid-19: Hamdard Labs to...

Covid-19: Hamdard Labs to begin clinical trials of immunity-boosting drugs Infuza, Kulzam

By - Ruchika Sharma
Published On 2020-09-08 06:49 GMT   |   Update On 2020-09-08 06:49 GMT

New Delhi: Health and wellness firm Hamdard Laboratories on Monday said it is going to start a clinical trial of its two immunity boosting medicines to assess their effectiveness in preventing COVID-19 infection. The company has received all the regulatory approvals to begin the proof of concept clinical trial for its Infuza and Kulzam drugs, Hamdard Laboratories said in a statement.A...

Login or Register to read the full article
Register Now

New Delhi: Health and wellness firm Hamdard Laboratories on Monday said it is going to start a clinical trial of its two immunity boosting medicines to assess their effectiveness in preventing COVID-19 infection. The company has received all the regulatory approvals to begin the proof of concept clinical trial for its Infuza and Kulzam drugs, Hamdard Laboratories said in a statement.

A research team from Hamdard Institute of Medical Sciences and Research (HIMSR) is going to start the clinical trial at HAH Centenary Hospital in New Delhi, it added.
"A research group of HIMSR, that comprises an allopathic doctor, unani hakim, microbiologist and biochemist is working on a randomised, parallel group clinical trial for the repurposing of two popular Hamdard medicines i.e. Infuza and Kulzum for the prevention of COVID-19 infection," Hamdard Laboratories India (Medicine Division) Executive Trustee Asad Mueed said.
HIMSR and associated HAH Centenary Hospital CEO G N Qazi said: "We are going to start the clinical trial...to evaluate the efficacy of these drugs for the prevention of COVID-19 infection in high risk subjects."
The study concept is approved by the Special Project Approval Committee, Ministry of AYUSH and has also been cleared by the Institutional Ethics Committee of the hospital, he added.



Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Alkem Laboratories Gets CDSCO Panel Nod to Study Amoxicillin,Clavulanate Powder for reconstitution into suspension
Bharat Biotech Chief Dr Krishna M Ella named as new President of Indian Vaccine Manufacturers Association
Pneubevax 14 safe, immunogenic in 6-8 week old infants: Biological E
Sun Pharma served with tax demand of Rs 1.11 crore
AstraZeneca Truqap plus Faslodex recommended for approval in EU by CHMP for advanced ER-positive breast cancer
Conduct bridging CT, prove efficacy, safety: CDSCO Panel Tells Glenmark on Roflumilast Cream of additional strength, indication
AstraZeneca admits 'very rare' side effect of COVID vaccine in UK court
Glenmark Pharma gets USFDA nod for Acetaminophen and Ibuprofen Tablets